Literature DB >> 7752192

Synthesis of novel imidazobenzodiazepines as probes of the pharmacophore for "diazepam-insensitive" GABAA receptors.

P Zhang1, W Zhang, R Liu, B Harris, P Skolnick, J M Cook.   

Abstract

The syntheses of a series of novel imidazobenzodiazepines and their affinities for diazepam sensitive (DS) and diazepam insensitive (DI) GABAA receptors are described. Imidazobenzodiazepines belong to one of the very few chemical families which exhibit high to moderate potency for DI GABAA receptors. Although imidazobenzodiazepines such as Ro 15-4513, 20, are the most potent DI GABAA receptor ligands described to date, their selectivity for DI versus DS GABAA receptors is only marginal. Previous structure-activity relationship (SAR) studies of imidazobenzodiazepines have indicated that the 3- and 8-positions are critical for high-affinity binding to DI GABAA receptors (J. Med. Chem. 1993, 36, 479-490. J. Med. Chem. 1993, 36, 1001-1006. J. Med. Chem. 1993, 36, 1820-1830). In order to determine why the ester function is critical to high affinity at the DI site, we have synthesized several derivatives which have substituents other than an ester at the C(3) position including 3-alkyl-, 3-alkylketo-, 3-alkyl ether, and 3-dialkylamino-substituted imidazobenzodiazepines. The SAR analysis of these compounds when combined with that of several pyrazoloquinolinones indicates that interactions at H1 and L1 as well as interactions at H2 anti to the imidazole N(2) and at a lipophilic pocket (labeled LDi) about the 3-position are required in order for imidazobenzodiazepines to exhibit selectivity and high affinity for DI GABAA receptors. Furthermore, the imidazobenzodiazepines substituted with an electron-donating group (alkoxy function) at position 8 revealed that the change of the substituent at C(8) from an electron-withdrawing to a donating function did not substantially alter either ligand affinity or selectivity for DI GABAA receptors. Thus, a pharmacophore is proposed for DI GABAA receptor ligands, which is characterized by the requirement of a lipophilic pocket LDi about the C(3) position of imidazobenzodiazepines. Using this model, two pyrazoloquinolinone derivatives were designed and synthesized. Their affinities and selectivities for DI GABAA receptors are consistent with those predicted by the DI GABAA receptor pharmacophore. In addition, examination of the in vitro binding data of 3-alkyl ether analogs confirms that the anti conformation of the ester group at the C(3) position of imidazobenzodiazepines (Ro15-4513, 20 series) is preferred at both DI and DS GABAA receptors. This constitutes the first evidence (other than molecular modeling) to support the auxillary involvement of H2 at the DI site and is important with regard to the synthesis of other DI GABAA receptor selective ligands in the future.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7752192     DOI: 10.1021/jm00010a013

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Allosteric modulation of GABA(A) receptor subtypes:effects on visual recognition and visuospatial working memory in rhesus monkeys [corrected].

Authors:  Paul L Soto; Nancy A Ator; Sundari K Rallapalli; Poonam Biawat; Terry Clayton; James M Cook; Michael R Weed
Journal:  Neuropsychopharmacology       Date:  2013-05-31       Impact factor: 7.853

2.  Cerebellar α6 -subunit-containing GABAA receptors: a novel therapeutic target for disrupted prepulse inhibition in neuropsychiatric disorders.

Authors:  Lih-Chu Chiou; Hsin-Jung Lee; Margot Ernst; Wei-Jan Huang; Jui-Feng Chou; Hon-Lie Chen; Akihiro Mouri; Liang-Chieh Chen; Marco Treven; Takayoshi Mamiya; Pi-Chuan Fan; Daniel E Knutson; Chris Witzigmann; James Cook; Werner Sieghart; Toshitaka Nabeshima
Journal:  Br J Pharmacol       Date:  2018-05-10       Impact factor: 8.739

3.  An Improved Process for the Synthesis of 4H-Imidazo[1,5-a][1,4]benzodiazepines.

Authors:  Jie Yang; Yun Teng; Shamim Ara; Sundari Rallapalli; James M Cook
Journal:  Synthesis (Stuttg)       Date:  2009-03       Impact factor: 3.157

4.  The α6 subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation.

Authors:  Pi-Chuan Fan; Tzu-Hsuan Lai; Chia Chun Hor; Ming Tatt Lee; Pokai Huang; Werner Sieghart; Margot Ernst; Daniel E Knutson; James Cook; Lih-Chu Chiou
Journal:  Neuropharmacology       Date:  2018-07-21       Impact factor: 5.250

Review 5.  A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model.

Authors:  Terry Clayton; Michael M Poe; Sundari Rallapalli; Poonam Biawat; Miroslav M Savić; James K Rowlett; George Gallos; Charles W Emala; Catherine C Kaczorowski; Douglas C Stafford; Leggy A Arnold; James M Cook
Journal:  Int J Med Chem       Date:  2015-11-10

6.  α6GABAA Receptor Positive Modulators Alleviate Migraine-like Grimaces in Mice via Compensating GABAergic Deficits in Trigeminal Ganglia.

Authors:  Hung-Ruei Tzeng; Ming Tatt Lee; Pi-Chuan Fan; Daniel E Knutson; Tzu-Hsuan Lai; Werner Sieghart; James Cook; Lih-Chu Chiou
Journal:  Neurotherapeutics       Date:  2020-10-27       Impact factor: 7.620

7.  Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability.

Authors:  Daniel E Knutson; Revathi Kodali; Branka Divović; Marco Treven; Michael R Stephen; Nicolas M Zahn; Vladimir Dobričić; Alec T Huber; Matheus A Meirelles; Ranjit S Verma; Laurin Wimmer; Christopher Witzigmann; Leggy A Arnold; Lih-Chu Chiou; Margot Ernst; Marko D Mihovilovic; Miroslav M Savić; Werner Sieghart; James M Cook
Journal:  J Med Chem       Date:  2018-03-06       Impact factor: 8.039

8.  Synthesis and preliminary structure-activity relationship study of 2-aryl-2H-pyrazolo[4,3-c]quinolin-3-ones as potential checkpoint kinase 1 (Chk1) inhibitors.

Authors:  Ivana Malvacio; Alberto Cuzzolin; Mattia Sturlese; D Mariano A Vera; E Laura Moyano; Stefano Moro
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.